Clinical In Vitro Maturation (IVM) represents a groundbreaking advancement in assisted reproductive technology (ART), offering a gentler, more patient-friendly approach to fertility treatment. Unlike conventional in vitro fertilization (IVF), IVM involves minimal or no ovarian stimulation, significantly reducing the risks and burdens associated with traditional protocols. This makes it an attractive option for a diverse group of patients seeking to fulfill their hope of parenthood.
This article will explore the evolution, protocols, benefits, and applications of Clinical In Vitro Maturation, with a focus on the advanced Biphasic IVM (CAPA-IVM) protocol developed and refined by pioneering institutions like IVFMD – My Duc Hospital.
What is Clinical In Vitro Maturation (IVM)?In Vitro Maturation (IVM) is a fertility treatment where immature oocytes (eggs) are retrieved from the ovaries and then matured in a laboratory setting before fertilization. This method contrasts sharply with conventional IVF, which relies on significant hormonal stimulation to mature eggs in vivo (within the body) before retrieval. The core principle of IVM is to obtain mature oocytes using no or minimal ovarian stimulation, making the process safer and less strenuous for patients.
The Evolution of IVM in Clinical Practice
The journey of IVM in clinical practice has seen significant advancements, particularly at institutions like IVFMD – My Duc Hospital. Since 2006, this hospital and its HOPE Research Center have conducted nearly 7,000 IVM cycles, leading to the birth of over 2,000 children.
Early IVM Protocols: h
CG-IVM and Standard IVMInitial IVM protocols included: - hCG-IVM: This protocol involved 2-6 days of FSH priming, followed by an hCG trigger before oocyte pick-up (OPU), and a one-step IVM culture. - Standard IVM: This approach used 0-3 days of FSH priming, no hCG trigger, and a one-step IVM culture.
However, these earlier protocols faced challenges, including low maturation rates, poor oocyte quality, and subsequently, a lower number and quality of embryos. These issues stemmed from early meiosis resumption, leading to a discrepancy between genetic and cytoplasmic maturation.
Biphasic IVM (CAPA-IVM): A Breakthrough
Recognizing the limitations of older methods, the Biphasic IVM protocol, also known as CAPA-IVM (Capacitation IVM), was introduced around 2016. This innovative approach aims to improve oocyte competence by mimicking the natural maturation process more closely.
The first CAPA-IVM baby was born in 2017. Since its inception, IVFMD has performed over 4,000 CAPA-IVM cycles, resulting in nearly 1,000 children born from this protocol. This demonstrates a significant step forward in optimizing IVM outcomes.
Understanding Biphasic IVM: The CAPA Concept
Biphasic IVM is designed to overcome the problems of older IVM protocols by preventing early meiotic resumption and promoting better oocyte-cumulus cell communication. The protocol involves two distinct steps in the laboratory:
Step 1: CAPA (Capacitation) – Prolonged Meiotic Arrest
This initial phase focuses on inducing cytoplasmic maturation while maintaining meiotic arrest. - Harvesting: Immature oocytes (fully surrounded COC - Cumulus Oocyte Complex) are collected from follicles. - Culture Medium: Oocytes are incubated for approximately 24 hours in a medium containing CNP (C-Type Natriuretic Peptide), Insulin, FSH, and Estradiol. - Goal: This step aims to prolong meiotic arrest and foster communication between the immature oocytes and surrounding cumulus cells (TransZonal Projections – TZPs), ensuring nuclear and cytoplasmic competence.
Step 2: IVM (In Vitro Maturation) – Induce Meiotic Reinitiation
Following the capacitation phase, the oocytes are transferred to a different medium to trigger maturation: - Culture Medium: Oocytes are incubated for approximately 30 hours in a medium containing AREG (Amphiregulin, an EGF-like factor), Insulin, FSH, and Estradiol. - Goal: This step induces meiotic reinitiation, leading to the development of MII (metaphase II) oocytes with mature cytoplasm, ready for fertilization.
Advantages of Clinical IVM over Ovarian Stimulation
Traditional ovarian stimulation for IVF comes with several drawbacks, which IVM aims to circumvent:
Reducing Risks and Complications - Ovarian Hyperstimulation Syndrome (OHSS): IVM significantly reduces or eliminates the risk of OHSS, a potentially severe complication of conventional IVF. - Complications of Large Ovaries: Avoids issues like bleeding, torsion, and tenderness associated with hyperstimulated ovaries. - Venous Thrombo-embolism: Minimizes the risk of VTE.
Lowering Burden and Cost - Reduced Medication Cost: Requires minimal or no expensive gonadotropin injections. - Less Monitoring: Fewer injections, blood tests, and ultrasounds. - Decreased Time and Effort: Less demanding on the patient's time for clinic visits and transportation. - Emotional Burden: A less intensive treatment course can alleviate significant emotional stress.
Potential Long-Term Benefits - Endometrial Acceptivity: High levels of FSH during the follicular phase in OS can affect endometrial receptivity and placentation. IVM avoids this. - Ovarian Health: Reduces concerns about potential long-term adverse effects on ovaries (e.g., cancer risk) from high hormonal exposure. - Baby Health: Ongoing research investigates the long-term health outcomes of IVM babies, with current findings suggesting comparable safety profiles to conventional IVF.
Who Can Benefit from Biphasic IVM?The ASRM Committee Opinion (2021) states that IVM is no longer experimental and has potential for wider application. It is recommended for specific indications and where sufficient expertise exists.
Key Candidates for Biphasic IVM - High Risk of OHSS: Especially women with Polycystic Ovary Syndrome (PCOS) or a high antral follicle count (AFC). - Poor Responders to FSH: Patients whose ovaries do not respond well to conventional FSH stimulation. - Gonadotropin Resistant Ovary Syndrome (GROS): IVM can be the only treatment option, as these ovaries do not respond to FSH at all, otherwise requiring oocyte donation. - Contraindications for Ovarian Stimulation: For example, women with hormone-sensitive cancers. - Fertility Preservation: For cancer patients prior to gonadotoxic treatments or for social egg freezing. - Low Ovarian Reserve: Emerging data suggest benefits even for women with reduced ovarian reserve. - Patients Seeking a Friendly ART Treatment: Those who prefer fewer injections, lower costs, and a less invasive approach. - Difficult Patients with Repeated Cycles: Offers an alternative when previous IVF attempts have failed.
Flashcards
Tap to flip · Swipe to navigate
Research and Clinical Outcomes of Biphasic IVMOngoing research and clinical trials have evaluated the efficacy and safety of Biphasic IVM (CAPA-IVM).
Efficacy in PCOS Women
A randomized controlled trial (Vuong et al., HR 2020) comparing Biphasic IVM to stimulated IVF in women with PCOS or high AFC showed a live birth rate of 35.2% for IVM versus 43.2% for IVF, with similar miscarriage rates and obstetric/perinatal outcomes. The IVM group produced >4 Day 3 embryos per patient.
Later iterations, like the Hormone-Free and Blastocyst protocol (Version 2.0, 2021), demonstrated a 38.3% live birth rate after one FET cycle, yielding an average of 3 blastocysts per patient. The Gonadotropin-Free and Fresh Blastocyst Transfer (The Sai Gon Protocol, Version 3.0, 2024) allows for fresh embryo transfer, further streamlining the process.
Applications Beyond PCOS - Advanced Maternal Age (36-44 years): Studies on Biphasic IVM in AMA women (mean age 37.2) show promising laboratory and clinical outcomes, including live births. - Non-PCOS, Good Ovarian Reserve: Pilot studies in non-PCOS patients with good ovarian reserve (AFC>15, AMH 3.60±0.84) demonstrated a live birth rate of 38.9% after the first embryo transfer. - Elective Egg Freezing: Biphasic IVM is being successfully used for elective egg freezing, with the first live birth from vitrified CAPA-IVM oocytes reported in 2024 for a 35-year-old woman with PCOS and endometriosis. - Ovarian Tissue Oocyte (OTO)-IVM: This advanced technique allows for the collection and maturation of oocytes from ovarian tissue, offering fertility preservation options for cancer patients. Retrieval rates of mature oocytes from cortical strips range from 40% to 64.7%.
Safety and Offspring Outcomes
Safety data from IVFMD's program (over 4,000 cycles, almost 1,000 Biphasic IVM babies) report no OHSS or other severe complications. Follow-up studies, including 2-year and 5-year data from randomized controlled trials, indicate that the development of children born from IVM is comparable to those born from IVF and natural conception.
The Future of IVM: The Saigon Biphasic-IVM Protocol
The Saigon Biphasic-IVM Protocol, a gonadotropin-free approach, aims for 3-4 blastocysts per cycle for PCOS women, expecting a high cumulative live birth rate. Pregnancy and perinatal outcomes are comparable to conventional ovarian stimulation IVF. This protocol can also be applied to non-PCOS women, broadening its reach and impact.IVM is continuously evolving, promising a more accessible, safer, and effective path to parenthood for a wider range of patients. The ongoing research and dedication of centers like IVFMD and the HOPE Research Center are crucial in fulfilling this hope for many.
Frequently Asked Questions About Clinical IVM
What are the main differences between IVM and standard IVF?The main difference is ovarian stimulation. Standard IVF involves significant hormonal injections to stimulate the ovaries and mature many eggs inside the body. IVM uses minimal or no stimulation, retrieving immature eggs that are then matured outside the body in the lab.
Is IVM as effective as conventional IVF?Early IVM protocols had lower success rates. However, with advancements like Biphasic IVM (CAPA-IVM), studies show comparable live birth rates in specific patient groups, particularly those with PCOS or at high risk of OHSS. The efficacy continues to improve with protocol refinements.
Are babies born from IVM healthy?
Research and follow-up studies, including 2-year and 5-year data from randomized controlled trials, indicate that the development and health of children born from IVM are comparable to those born from conventional IVF and natural conception.